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Key Messages
• This study was designed to identify and quantify macrophage populations and any associations with ICC in the
normal human stomach and in gastroparesis.
• Quantification of immunoreactive cells using CD45, cKit, CD206 and iNOS was carried out on gastric body
biopsies from 10 age-matched, female patients from each of the following groups; Controls, Diabetic Controls,
Idiopathic Gastroparesis, and Diabetic Gastroparesis.
• Macrophages appear to play a cytoprotective role in the human stomach. There is a relationship between numbers
of CD206 positive (alternatively activated, M2) macrophages and numbers of ICC in diabetic gastroparesis.
• The data suggest that therapeutic strategies may be explored that target alternatively activated macrophages.
Abstract
Background There is increasing evidence for specific
cellular changes in the stomach of patients with
diabetic (DG) and idiopathic (IG) gastroparesis. The
most significant findings are loss of interstitial cells of
Cajal (ICC), neuronal abnormalities, and an immune
cellular infiltrate. Studies done in diabetic mice have
shown a cytoprotective effect of CD206+ M2 macro-
phages. To quantify overall immune cellular infiltrate,
identify macrophage populations, and quantify
CD206+ and iNOS+ cells. To investigate associations
between cellular phenotypes and ICC. Methods Full
thickness gastric body biopsies were obtained from
non-diabetic controls (C), diabetic controls (DC), DG,
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and IG patients. Sections were labeled for CD45,
CD206, Kit, iNOS, and putative human macrophage
markers (HAM56, CD68, and EMR1). Immunoreactive
cells were quantified from the circular muscle layer.
Key Results Significantly fewer ICC were detected in
DG and IG tissues, but there were no differences in the
numbers of cells immunoreactive for other markers
between patient groups. There was a significant corre-
lation between the number of CD206+ cells and ICC in
DG and DC patients, but not in C and IG and a
significant correlation between iNOS+ cells and ICC in
the DC group, but not the other groups. CD68 and
HAM56 reliably labeled the same cell populations, but
EMR1 labeled other cell types. Conclusions & Infer-
encesDepletion of ICC and correlationwith changes in
CD206+ cell numbers in DC and DG patients suggests
that in humans, like mice, CD206+macrophages may
play a cytoprotective role in diabetes. These findings
may lead to novel therapeutic options, targeting alter-
natively activated macrophages.
Keywords gastroparesis, interstitial cells of Cajal,
macrophages.
Therapies for gastroparesis have not changed signifi-
cantly for many years and gastroparesis remains a
significant challenge for both patients and providers.1–4
Gastroparesis continues to be a significant and costly
health issue.2,5,6 Animal models have recently begun to
provide new information on the pathophysiology of
gastroparesis with identification of several new targets,
including enteric nerves,7,8 interstitial cells of Cajal
(ICC)8–11, and most recently macrophages.11,12 There
are now several animal model and human tissue studies
that show that ICC are reduced in gastroparesis. A
recently published study from the NIH sponsored Gast-
roparesis Clinical ResearchConsortium showed that loss
of ICC is the most common defect seen and occurs in
both human diabetic and idiopathic gastroparesis (IG).13
Neuronal changes were also seen, especially at the
electron microscopy level.14 The studies also showed
that CD45 positivity, used as generic marker of immune
cells, was increased in a subset of patients in the
myenteric plexus of gastroparetic patients.13 No correla-
tion between CD45-positive cell infiltrate and ICC loss
was found in either diabetic or IG.15
Animal studies have suggested an important role of
macrophages in the pathophysiology of gastropare-
sis.11,12 Studies in diabetic non-obese diabetic mice
have suggested that a defined series of events leads to
development of delayed gastric emptying. These events
are closely linked to changes in the phenotype of
macrophage populations in the muscularis propria as
indicated by the expression of well-defined markers for
mouse macrophages. All macrophages in the mouse
stomach are immuno-labeled with F4/80, a monoclo-
nal antibody against a membrane glycoprotein, this
includes resident, classically activated, and alterna-
tively activated macrophages.16,17 Classically activated
macrophages, also known as M1 macrophages, express
inducible nitric oxide synthase (iNOS, NOS2) among
other markers and nitric oxide (NO) is an important
cytotoxic product of these cells.18,19 Alternatively
activated or M2 macrophages express the mannose
receptors (CD206) and heme oxygenase-1 (HO1) and
mediate cell repair and have anti-inflammatory
roles.18,19 In mice, under normal conditions, develop-
ment of diabetes and the concomitant increase in
oxidative stress result in activation of M2 macrophages
that are protective against development of delayed
gastric emptying. In susceptible animals, prolonged
diabetes leads to loss of the M2 macrophages and
increased numbers of HO1-negative, M1 macrophages
that express iNOS, damage to ICC networks, and
development of delayed gastric emptying.11,12
It is not known if the findings in the mouse models
are also applicable to human gastroparesis. The classi-
fication of human macrophages is not as well defined
as for mouse cells and human macrophages do not
appear to express iNOS20 due to an epigenetic silencing
mechanism that is present in human, but not mouse
macrophages.21 However, alternatively activated, M2-
like human macrophages do express the mannose
receptor (CD206).19 For general markers, several have
been proposed to label all macrophage types in a
variety of tissues. These include CD68, a cell surface
marker identified on the majority of macrophages22,
but also found on other cell types,23 HAM56, which is
expressed on a broad range of cells belonging to the
macrophage lineage24,25,26 albeit with some evidence
for labeling of endothelial cells25 and EMR1, the
human homolog of F4/80.27 Identification of the
involvement of macrophages may identify new thera-
peutic targets, but there has been limited characteriza-
tion of macrophages in the muscularis propria of
human gastrointestinal tissue.17,28–30 In this study,
we assessed the reliability of HAM56, CD68, and
EMR1 as selective markers of macrophages in human
gastric muscularis propria. We also quantified CD45-
positive cells as a measure of general immune cell
infiltrate in tissues from patients with diabetic and IG,
quantified CD206-positive cells as a measure of anti-
inflammatory macrophages, quantified iNOS-positive
cells as a measure of an increased inflammatory
environment in the tissues, and studied the
relationship between CD45, CD206, and iNOS-posi-
tive cell numbers and ICC numbers.
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METHODS
Full thickness biopsies of the gastric body were
studied from 10 age-matched female patients in four
different groups. Control tissues were obtained during
bariatric surgery from non-diabetic (C) (median age 46;
age range 26–59) and diabetic control (DC; median age
49; age range 33–59) patients with no motility disor-
ders. Tissue from patients with diabetic gastroparesis
(DG), all with Type I diabetes (median age 43; age
range 28–60) and IG (median age 44; age range 26–64)
were obtained at the time of gastric electrical stim-
ulator implantation, as previously described.13 Immu-
noreactive cells were quantified from eight non-
adjacent, 12 lm frozen sections, from each patient.
Images were collected from 48 fields in the circular
muscle (CM) layer of doubly labeled sections, using a
409/1.0 NA, UPlanApo, oil immersion Olympus objec-
tive and XM10 digital camera. Cells were counted from
images that were de-identified by renaming with a
random number generated using a web-based random
number generator (www.random.org). Immunoreactive
cells were defined as a positively labeled structure
with a 4’,6-diamidino-2-phenylindole (DAPI)-positive
nucleus within the structure.
Immunohistochemistry was done as follows. In one
set, we doubly labeled sections using a mouse mono-
clonal antibody against Kit as a marker for ICC (US
Biological, Salem, MA, USA) and a goat polyclonal
antibody to CD206 (Santa Cruz, Santa Cruz, CA ,
USA) as a marker for M2 (alternatively activated
macrophages). Sections of tissue were warmed to
room temperature in a desiccator and rinsed twice in
1X PBS followed by a blocking step for non-specific
antibody binding by incubating the tissue in 1X PBS,
1% bovine serum albumin (BSA), and 0.3% Triton X-
100 for an hour at room temperature. The antibodies
(Table S1) were diluted in 1X PBS, 1% BSA, and 0.3%
Triton X-100, and incubated overnight at 4 °C. Next,
slides were rinsed in 1X PBS five times, followed by a
1 h incubations with secondary antibodies (Table S1)
diluted in 1X PBS, 1% BSA, 0.3% Triton X-100 at
room temperature. The slides were rinsed five times
in 1X PBS and mounted in SlowFade Gold with DAPI
(Invitrogen, Carlsbad, CA, USA). In another set, we
doubly labeled sections using a mouse monoclonal to
CD45 (AbD Serotec, Raleigh, NC, USA) as a general
marker for immune cell infiltrate and a rabbit poly-
clonal to iNOS (Thermo Scientific, Pittsburgh, PA,
USA) as an indicator of increased inflammatory cells
in the tissues. Slides were rinsed twice in 1X PBS,
followed by an addition of Image-iT FX Signal
Enhancer for 30 min. The slides were rinsed twice
in 1X PBS, followed by a 1 h block with 1X PBS, 1%
BSA, 0.3% Triton X-100. Primary antibodies were
added in 1X PBS, 1% BSA, 0.3% Triton, and incubated
overnight at 4 °C. The protocol was finished as
described above.
There is a lack of a well-established, well-validated
general marker for human macrophages in gastric
muscularis propria. Therefore, we investigated several
different antibodies which have been published as
markers for human macrophages. These included CD
68 (mouse monoclonal, DAKO, Carpinteria, CA,
USA),31 EMR1 (rabbit polyclonal, MBL International,
Woburn, MA, USA)27, and HAM56 (mouse monoclo-
nal, Thermo Scientific).32 We also doubly labeled for
CD68 with HAM56, CD68 with EMR1, and HAM56
with EMR1. The protocol for immunohistochemistry
on the doubly labeled slides using Ham 56 and EMR1
was followed as described above. In the slides doubly
labeled for CD68 (mouse monoclonal, Isotype IgG3,
kappa) and HAM56 (mouse monoclonal, Isoptype IgM)
the protocol is as follows. Sections of tissue were
warmed to room temperature in a desiccator. While
tissue is warming, place 1 mM EDTA, pH 8.0 in a
plastic coplin jar and heat in a 60° water bath. Rinse
slides for 2 min, twice in 1X PBS. Place slides in heated
EDTA and heat for 60 min in uncovered jar in water
bath. Remove Coplin jar from water bath, let slides
cool in EDTA for 5 min while covered. Rinse slides
under faucet with cool running distilled water for
5 min. Rinse slides twice in 1X PBS for 5 min,
followed by a 1 h block in 1X PBS, 1% BSA, and
0.3% Triton X-100 at room temperature. HAM56 was
diluted in blocking buffer and added to the slides and
incubated overnight at 4 °C. The next day, slides were
rinsed five times in 1X PBS for 5 min and the
secondary antibody (IgM) was added and incubated for
1 h. The slides were then rinsed five times in 1X PBS
for 5 min followed by a 1 h block in 1X PBS, 1% BSA,
and 0.3% Triton X-100 at room temperature. CD68
was diluted in blocking buffer and added to the slides
and incubated overnight at 4 °C. The next day slides
were rinsed five times in 1X PBS for 5 min and the
secondary antibody (IgG) was added and incubated for
1 h. Slides were rinsed five times in 1X PBS and
mounted in SlowFade Gold with DAPI (Invitrogen). For
all antibodies used, we carried out serial dilutions to
determine the optimal antibody titers and positive and
negative controls.
Statistical differences were determined using one-
way ANOVA and correlations were determined by fitting
using linear regression in Prism (Graphpad, La Jolla,
CA, USA).
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RESULTS
There were significantly fewer ICC detected in the CM
layer of gastroparetic samples when compared to
control samples (p = 0.0171 by one-way ANOVA, with
Newman–Keuls posttest, Fig. 1; DG: 1.67  0.6, IG:
2.1  0.5, C: 4.95  1.2, DC: 3.8  0.72 ICC/field,
n = 10, p < 0.05, ANOVA). This finding is consistent
with our previous findings.13 An immune infiltrate
was present within the CM layer of all four groups
(Fig. 2). On quantification, the number of CD45-
positive cells was not different between the four groups
(p < 0.05, one-way ANOVA, Fig. 2; DG: 8.61  0.8, IG:
9.48  1.1, DC: 9.85  1.99, C: 8.90  0.7 cells per
field). There were no significant correlations for any of
the four groups (Fig. 3) between numbers of CD45-
positive cells and ICC.
To investigate which pan-macrophage marker is best
to use in the human stomach wall, we tested and
compared labeling of CD68, EMR1, and HAM56. We
observed that CD68 immunoreactivity overlapped
with HAM56 immunoreactivity in the vast majority
of cells (Fig. 4). However, there were some HAM56-
positive cells that were CD68 negative (arrows in
Fig. 4C) and CD68-positive cells that were HAM56
negative (arrowheads in Fig. 4C). CD68 double labeled
with EMR1 showed little overlap between cells.
EMR1-positive cells were more abundant than CD68-
positive cells. There were either CD68-positive cells or
EMR1-positive cells but not both suggesting each
labeled a separate population. This observation was
supported by doubly labeling for HAM56 and EMR1.
This observation showed little overlap between the
two populations with more HAM56-positive cells that
were EMR1 negative and some EMR1 positive but
HAM56-negative cells. These data suggest that CD68
and HAM56 are better markers for the total macro-
phage population in the human stomach than EMR1.
In diabetic non-obese diabetic mice, the presence of
CD206-positive macrophages is associated with pro-
tection against the development of delayed gastric
emptying. In this mouse model, CD206 macrophages
are present in large numbers in mice with diabetes
with normal gastric emptying and decreased in mice
with diabetes and delayed gastric emptying. CD206 (a
marker for M2, alternatively activated macrophages)-
positive cells were quantified in the CM layer of all
four groups (Fig. 5). CD206-positive cell numbers were
not significantly different in any of the four groups
(p > 0.05, one-way ANOVA, Fig. 5) with a wide variation
in the number of CD206-positive cells per field.
However, there was a significant correlation between
number of CD206-positive cells and numbers of ICC
in both DC samples (p = 0.0285) and diabetic gastro-
paretic samples (p = 0.001, Fig. 6). There was no
Figure 1 Significantly fewer ICC were detected in the circular muscle
layer of Idiopathic Gastroparesis (IG, 2.1  0.5 cells/field) and Diabetic
Gastroparesis (DG, 1.67  0.6 cells/field) compared to Controls
(C, 4.95  1.2 cells/field) and Diabetic Controls (DC, 3.8  0.72 cells/
field). Data show average values for counts from 39 fields from each
patient as points, population means  SEM shown as whiskers, n = 10
patients for each group, * indicates p < 0.05, one-way ANOVA with
Newman–Keuls posttest.
A B
C
E
D
Figure 2 Representative images for CD45 immunoreactivity in the
gastric circular muscle layer from (A) Control (B) Diabetic Control (C)
Idiopathic Gastroparesis (D) Diabetic Gastroparesis; scale
bar = 100 lM. (E) Number of CD45-positive cells was not different
between the four groups. Data show average values for counts from 39
fields from each patient as points, population means  SEM shown
whiskers, n = 10 patients for each group, p > 0.05, one-way ANOVA.
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significant correlation between CD206-positive cells
compared to numbers of ICC in control and idiopathic
gastroparetic samples (p < 0.05, Fig. 6).
Development of delayed gastric emptying is associ-
ated with the presence of M1 classically activated
macrophages in the gastric wall in diabetic mice.12
These cells express high levels of iNOS, so we
investigated whether iNOS immunoreactivity was
different in the tissues from the four groups. The
numbers of iNOS-positive cells were not different
between the four groups (p = <0.05, Fig. 7). However,
there was a significant correlation between the num-
bers of iNOS-positive cells and the numbers of ICC in
the DC group (p = 0.0012), but not in any of the other
groups (Fig. 8). To determine the percentage of iNOS-
positive cells that were positive for an immune cell
marker, we doubly labeled the tissues for iNOS and
CD45. Only a small portion of iNOS-positive cells
were CD45-positive in all four groups (DG: 22  2%,
IG: 19  2%, DC: 32  5%, C: 30  5%), an observa-
tion that is consistent with iNOS being a poor marker
for classically activated macrophages in the human
stomach.
DISCUSSION
Animal models have provided highly valuable infor-
mation on the cellular changes associated with the
development of DG. A major finding emerging from
these models is the unexpected role macrophages
play in the pathophysiology of DG and the relation-
ship between macrophage type and disruption of
the number or function of key cell types involved in
the regulation of gastric motility such as enteric
nerves and ICC.11,12 The current study was designed
to determine if similar changes also occur in human
gastroparesis and if there were differences
between diabetic and IG. The study builds on a
previously reported finding by the NIH funded gast-
roparesis clinical research consortium of a CD45-
positive infiltrate in a subset of patients with
gastroparesis.13
Several conclusions may be made from the data. We
found, using a different cohort of patients from the
previously reported study from the gastroparesis clin-
ical research consortium,13 that there was a decrease in
ICC numbers in the CM of gastroparetic samples
A B
C D
Figure 3 No correlation between number of
CD45-positive cells and ICC (A) Control:
r2 = 0.111, Slope = 0.536  0.538;
(B) Diabetic Control: r2 = 0.335,
Slope = 0.209  0.104; (C) Idiopathic
Gastroparesis: r2 = 0.3215,
Slope = 0.241  0.124; (D) Diabetic
Gastroparesis: r2 = 0.008,
Slope = 0.062  0.238. Each point
represents the data from a single patient and
are means  SEM for counts from 39 fields.
Data were fit by linear regression using
Graphpad Prism. Dark line shows the fit,
Gray dotted lines show the 95% confidence
limits for the fit.
A B C
Figure 4 Representative images of macrophages markers (A) CD68 (B) HAM56 (C) Merged image (CD68 green) and (HAM56 red) in the circular
muscle layer from the gastric body. White arrowhead shows CD68-positive, HAM56-negative cells. White arrow shows CD68-negative, HAM56-
positive cells; scale bar = 100 lM.
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compared to controls. This is in agreement with a
growing number of human studies that show similar
levels of loss of ICC in both diabetic and IG14,33–40 and
a correlation between the degree of ICC loss and gastric
emptying in DG.15
The main finding of this study is that there was a
significant correlation between number of ICC and
CD206 numbers in diabetic gastric tissue and diabetic
gastroparetic tissue. This is consistent with the finding
in mice that CD206-positive M2 macrophages are
protective12 and suggests that a similar mechanism is
operative in DG. However, there are also differences. In
the mouse, M1 and M2 macrophage numbers in the
stomach wall were relatively discordant. That is, in
diabetic mice with normal gastric emptying over 90%
of macrophages were M2 macrophages, whereas in
diabetic mice with delayed gastric emptying less than
5% of macrophages had the M2 phenotype. In humans,
it appears that both types of macrophages are present
and it is the relative percentage that determines
cytoprotection vs injury.
However, a significant caveat is that much less is
knownabout the subtypes of humanmacrophages,what
receptors are expressed and if and how they vary from
organ to organ. It still remains unclear whether human
CD206-positive macrophages have a similar cytopro-
tective function as mouse M2 macrophages. In mice, a
reliable and relatively specific pan-macrophage marker
is F4/80.16 F4/80 is a membrane protein shown to be a
marker for mature mouse macrophages and blood
monocytes.16,41 The exact role of F4/80 is not known,
but the sequence has adhesion and signaling domains
suggesting a potential role in these pathways.16,41 The
human homolog of F4/80 is EMR1,42 located on chro-
mosome 19 with 68% sequence homology to F4/80.
EMR1 has therefore been used as a marker for human
macrophages.27,43We found that EMR1 is a poormarker
for human gastric macrophages as there was practically
no overlap between EMR1-positive cells and CD68 or
HAM56, both published as human macrophage mark-
ers.29,32,44,45 Our finding is in line with a study exam-
ining the surface expression of EMR1 using quantitative
real-time PCR and flow cytometry. This study also
found that EMR1 was not expressed on monocytes or
macrophages, but labeled eosinophils in humans.27
EMR1 should therefore not be used as a human macro-
phage marker. Hamann et al. suggest that EMR1 is a
specific human eosinophilmarker, but the large number
of cells labeledwith EMR1 in the human stomach in our
study suggest it is not specific to eosinophils. In contrast
to EMR1, therewas general agreement between labeling
using CD68 or HAM56 antibodies. The number of cells
labeled and the fact that there were some HAM56-
positive cells that were CD68 negative as well as CD68-
positive cells that were HAM56 negative suggests that
the antibodies are labeling other cell populations
together with macrophages and/or that they label
different subsets of macrophages. Our data, taken with
the literature23,27,46 suggest that both can be used as
macrophage markers, but that care must be taken in
interpreting results obtained using these antibodies as
other studies carried out using CD68 as a macrophage
marker have found that CD68 labels other hematopoi-
etic and non-hematopoietic cells.23,47
iNOS is expressed in M1 macrophages in mice48 and
some studies have reported transient expression of
iNOS in human cells of the macrophage/monocyte
lineage.49 We were therefore interested to see if iNOS
expression was present in the human stomach wall, if
it could be used as a marker for human gastric
macrophages and if expression varied between gastro-
paresis and normal gastric emptying. We found no
difference in the expression of iNOS across all four
groups. Less than a third of iNOS-positive cells were
A B
C
E
D
Figure 5 Representative images for CD206 immunoreactivity in the
gastric circular muscle layer from (A) Control (B) Diabetic Control (C)
Idiopathic Gastroparesis (D) Diabetic Gastroparesis; scale
bar = 100 lM. (E) Number of CD206-positive cells was not different
between the four groups. Data show average values for counts from 39
fields from each patient as points, population means  SEM shown
whiskers, n = 10 patients for each group, p > 0.05, one-way ANOVA.
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CD45 positive suggesting that the majority of iNOS-
positive cells in the human gastric muscle wall are not
immune cells and therefore not macrophages. iNOS
therefore cannot be used as a specific marker for either
immune cells or specifically M1 macrophages in the
stomach. Some of the iNOS-positive cells had the
visual appearance of fibroblast like type cells. We did
double labeled iNOS with PDGFRa and Kit (data not
shown). There was no overlap between iNOS and
PDGFRa nor iNOS and Kit suggesting that these cells
were not fibroblast like cells nor ICC. This finding also
suggests that the iNOS antibody is not a suitable
marker for M1, classically activated macrophages.
There currently are no other markers that have been
shown to label M1 macrophages and also label human
macrophages. Development of such markers is neces-
sary to allow the field to progress and also address
relationships between M1 macrophages disease sub-
types. In our initial report,13 we found an immune
infiltrate in the human stomach with a qualitative
increase in number of CD68-positive cells in the
myenteric region in a subset of patients with gastro-
paresis. Antibodies used for B cells (CD79), T cells
(CD3), and T-helper cells (CD4) showed no differences
in immunolabeling between controls and gastroparetic
samples.13 This suggested that the immune cell infil-
trate was not due to B or T cells. The current study
using a more rigorous quantitative methodology
showed that there was indeed a CD45-positive
immune cell infiltrate in the CM, but it was not
different among the four groups. The association
between number of CD206-positive cells and ICC
suggest that together with quantifying numbers and
determining the type of immune cells, the relative
numbers of different cell types (e.g., M1 vs M2
macrophages) and the spatial relationship between
A
C D
B
Figure 6 Correlation between number of
CD206-positive cells and ICC. There was no
correlation between CD206-positive cells
and ICC in (A) Controls and (C) Idiopathic
Gastroparesis. There was a significant
correlation between CD206-positive cells
and ICC in (B) Diabetic Controls
(p = 0.0285) and (D) Diabetic Gastroparesis
(p = 0.001). Each point represents the data
from a single patient and are means  SEM
for counts from 39 fields. Data were fit by
linear regression using Graphpad Prism.
Dark line shows the fit, Gray dotted lines
show the 95% confidence limits for the fit.
A B
C D
E
Figure 7 Representative images for iNOSimmunoreactivity in the gastric
circularmuscle layer from (A)Control (B) DiabeticControl (C) Idiopathic
Gastroparesis (D)DiabeticGastroparesis. (E)NumberofiNOS-positivecells
isnotdifferentbetweenthefourgroups.Datashowaveragevaluesforcounts
from39fieldsfromeachpatientaspoints,populationmeans  SEMshown
whiskers, n = 10 patients for each group (p > 0.05, one-way ANOVA).
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cells may also be of importance. This will need to be
addressed in future studies.
At an immunohistochemical level, few differences
are apparent between diabetic and IG13,14 with loss of
ICC and neuronal abnormalities described in both
groups and differences limited largely to the transmis-
sion electronmicroscopy level. Thefinding in this study
of a relationship between number of CD206-positive
cells and number of ICC in diabetic but not IG suggests
that while the end cellular damage at a lightmicroscopy
level is similar, the mechanisms that lead to such
damage may be very different. This is perhaps not
surprising given the high levels of reactive oxygen
species and oxidative stress associated with diabetes.50
In conclusion, the main finding of this study is that
there is a relationship between numbers of human
CD206-positive macrophages and numbers of ICC
suggesting that, in agreement with previous animal
studies, CD206-positive macrophages may play a
cytoprotective role in the human stomach. This
finding opens up the opportunity to develop therapeu-
tic strategies that target alternatively activated CD206-
positive macrophages.
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